▶ Freely access a vast video library on NASH and NAFLD, its management and diagnosis along with the latest on pan-PPAR agonist, lanifibranor.
Nash Videos
Clinical Data Warehouse : definitions and use cases
Prof. Stéfan Darmoni, France, discusses the clinical data warehouses (CDW) where he explains its definitions and various use cases.
View More ⏩
NAFLD / NASH as a Metabolic Disease: Improving Patients Outcomes – Part 2
Prof. A.G.(Onno) Holleboom, Netherlands, discusses non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) as a metabolic disease and reviews management strategies in order to improve patients outcomes.
View More ⏩
Cancers and NASH
Dr. Jean-François Dufour (Switzerland) reviews the association between cancers and NASH, where he highlights the causes of death in NAFLD patients, in which cardiovascular diseases and non-liver cancer with 38.3% and 18.7% are identified as some of the major causes.
View More ⏩
Link between NAFLD and HFpEF
Dr. Marat Fudim (USA) reviews the interaction between NAFLD and Heart Failure with preserved Ejection Fraction (HFpEF), including highlights of the global prevalence rate of NAFLD.
View More ⏩
Interactions between gut microbiota and PPARs in NAFLD
Dr. Nicolas Lanthier (Belgium) reviews the interaction between the gut microbiota and PPARs in NAFLD. He discusses the microbiota and its link to NAFLD and IR, where he explains the key role of the gut microbes in the metabolism of their host and highlights how liver becomes the first organ to be exposed to gut changes.
View More ⏩
Lifestyle Treatment for NAFLD in Daily Practice
Pr Zelber Sagi explains there is an option for life's treatment at each stage of non-alcoholic fatty liver disease NAFLD with lifestyle examples in clinical practice.
View More ⏩
NASH and CV disease: new considerations
NASH is increasing with the current obesity pandemic. Prof. Robert Chilton (San Antonio - USA) reminds us that the current best practices to tackle the burden of this multi-system disease are currently lifestyle interventions
View More ⏩
New insights into the role of inflammation in NAFLD
Dr. Moritz Peiseler (La Charité - Germany), discusses new scientific insights into the role of inflammation in NAFLD / NASH. He presents the spectrum of NAFLD and explains how inflammation can drive all the progressive stages of NAFLD. He also reviews hepatocellular carcinoma (HCC) risks and presents several studies and evolving treatments for NASH.
View More ⏩
Lifestyle prevention & treatment for NAFLD
Currently, there are no Food and Drug Administration (FDA)-approved or European Medicines Agency (EMA)-approved therapies for NASH and only lifestyles interventions are recommended for the treatment of NAFLD. Prof Zelber-Sagi (Haifa, Israel) reviews best practices for lifestyle interventions in patients with NAFLD. She warns us against ultra-processed foods and drinks, that are so common in the Western world. She also highlights the benefits of the Mediterranean diet and physical activity.
View More ⏩
Liver sinusoidal endothelial cell (LSEC) capillarization in NASH
Prof. Pierre-E.Rautou (France) discusses the effects of Liver Sinusoidal endothelial cell (LSEC) capillarization in patients with NASH. He also reviews the occurrences of LSEC capillarization at the early stages of NASH and its contribution to NASH progression by favoring inflammation and liver fibrosis. For the clinicians, he demonstrates a 24 week study of patients with NASH, exposed placebo and lanifibranor treatments strategies to determine LSEC changes.
View More ⏩
The Course of Liver Histology and Morbi-Mortality in NAFLD / NASH
Prof. Manuel Romero-Gomez discusses the course of liver histology and its impact on mortality and morbidity in patients with NAFLD and NASH. He clarifies how fibrosis determines the prognosis of NAFLD and is the main therapeutic target. The importance of steatosis is also discussed both at the early phase and advanced phase. Finally he reviews the association with HCC and CV risks.
View More ⏩
The Complex Interaction Between Body Weight and NAFLD / NASH
NAFLD is strongly associated with obesity and metabolic disease. Obesity has clinical implications that extend beyond the liver. It is associated with insulin resistance which plays an important role in NASH. Agents with combined PPAR agonism may hold significant potential in this regard.
View More ⏩
SUBSCRIBE & FOLLOW US
SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES